By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





Company News
Regeneron (REGN)'s Schleifer Amongst The Best Compensated CEOs In New York 12/24/2014 8:37:29 AM
Regeneron (REGN), Sanofi (SAN.PA) Test The Public's Cholesterol IQ To Prep For Alirocumab Launch 12/16/2014 6:05:01 AM
Regeneron (REGN) CEO Says He's Sticking To Plan To Double NY Workforce, Lauds Funding "Halo" 12/12/2014 6:48:40 AM
Ablexis Announces Availability Of The AlivaMab Mouse Technology And Settlement Of The Litigation With Regeneron (REGN) 12/4/2014 2:01:25 PM
Ablexis Announces Availability Of The AlivaMab Mouse Technology And Settlement Of The Litigation With Regeneron (REGN) 12/4/2014 9:50:12 AM
Regeneron (REGN) Release: EYLEA (aflibercept) Injection Accepted For Priority Review By FDA For Diabetic Retinopathy In Patients With Diabetic Macular Edema 12/1/2014 9:33:14 AM
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/20/2014 5:45:20 AM
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/19/2014 7:54:40 AM
Regeneron (REGN) Announces EYLEA (aflibercept) Injection Approved For The Treatment Of Diabetic Macular Edema (DME) In Japan 11/18/2014 1:56:06 PM
Regeneron (REGN)'s Eylea Gets Japanese Nod For Macular Edema 11/18/2014 8:04:16 AM
12345678910...
//-->